Can the personalized medicine approach contribute in controlling tuberculosis in general and India in particular?

Poor drug compliance and drug-resistant Mycobacterium tuberculosis are the two principal obstacles in controlling tuberculosis (TB) in endemic regions including India, which has contributed the most to global TB burden. We argue here that a personalized medicine approach, to start with the N -acetyl transferase-2-isoniazid (NAT2-INH) model, could be a step forward in dealing with both these limitations in controlling TB in India.